Clinical trial · Observational
Performance of Amino Acid Positons Emission Tomography in Brain Metastases
Static and Dynamic Performance of Amino Acid Positons Emission Tomography (PET) for Differentiating Radiation Necrosis From Tumor Progression in Irradiated Brain Metastases (DYNAMET)
NCT07676448CI-TRIAL-00118373DYNAMETnot yet recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Differentiating radiation necrosis from tumor progression in patients with brain metastases has a major therapeutic and prognostic implications
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| PET-CT | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| PET exam analysis | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- To compare the diagnostic performance amino acid PET imaging
- timeFrame
- Day 1
- description
- Uptake of tumor
Secondary outcomes (1)
- measure
- To evaluate the potential impact of immunotherapy administered before or during PET imaging
- timeFrame
- 2 weeks
- description
- MRI results
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: * Patients who received a PET amino acid for differentiating radiation necrosis from progression of irradiated brain metastases, Exclusion Criteria: * Patients who refused the using of their data
References
Publications (0)
Data not yet available
No reference posted for this study.